Table 5.
Multivariate analysis for the effects of receptor for advanced glycation end products (RAGE) genetic polymorphism and various clinicopatholgical parameters on the recurrence-free survival and overall survival of the patients with uterine cervical cancer
| Recurrence-free survival | Overall survival | |||
|---|---|---|---|---|
| Variable | p value | HR & 95% CIb | p value | HR & 95% CIb |
| RAGE genetic polymorphism | ||||
| rs1800624 TA/AA vs TTa | 0.409 | 0.54 (0.12-2.36) | 0.330 | 0.36 (0.04-2.85) |
| Clinicopathological characteristics | ||||
| Stage | ||||
| ≥ stage II vs stage Ia | 0.004 | 3.86 (1.56-9.55) | >0.05 | u.a. |
| Pelvic lymph node | ||||
| metastasis vs no metastasisa | >0.05 | u.a. | 0.009 | 3.30 (1.35-8.08) |
aAs a comparison reference
bHR, hazard ratio and 95% CI, 95% confidence interval for RAGE genetic polymorphism and clinicopathological variables, compared to their respective controls.
u.a.: unavailable